US 11,692,983 B2
Quality control reagents and methods
Joshua Jacques Coon, Middleton, WI (US); Michael M. Rosenblatt, Middleton, WI (US); and Marjeta Urh, Madison, WI (US)
Assigned to Promega Corporation, Madison, WI (US)
Filed by Promega Corporation, Madison, WI (US)
Filed on Jan. 27, 2021, as Appl. No. 17/159,923.
Application 16/275,417 is a division of application No. 14/180,125, filed on Feb. 13, 2014, granted, now 10,247,711, issued on Apr. 2, 2019.
Application 17/159,923 is a continuation of application No. 16/549,769, filed on Aug. 23, 2019, granted, now 10,908,135.
Application 16/549,769 is a continuation of application No. 16/275,417, filed on Feb. 14, 2019, granted, now 10,900,939, issued on Jan. 26, 2021.
Claims priority of provisional application 61/764,312, filed on Feb. 13, 2013.
Prior Publication US 2021/0156832 A1, May 27, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 30/86 (2006.01); G01N 30/02 (2006.01); H01J 49/00 (2006.01); G01N 30/04 (2006.01); G01N 30/88 (2006.01)
CPC G01N 30/8665 (2013.01) [G01N 2030/027 (2013.01); G01N 2030/047 (2013.01); G01N 2030/8831 (2013.01); H01J 49/0009 (2013.01)] 20 Claims
 
1. A peptide mixture comprising three or more distinct-mass versions of each of three or more distinct-sequence peptides, wherein two or more of the distinct-mass versions of each distinct-sequence peptide comprises one or more amino acids with above natural-abundance levels of one or more heavy isotopes, and wherein the distinct-sequence peptides:
do not contain one or more of tryptophan, methionine, cysteine, proline, asparagine, glutamine, or histidine residues; and/or
do not contain internal lysine or arginine residues.